




PHARMACEUTICAL 2021

KalVista Pharmaceuticals Inc.
Rank 147 of 409





PHARMACEUTICAL 2021

KalVista Pharmaceuticals Inc.
Rank 147 of 409



The relative strengths and weaknesses of KalVista Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of KalVista Pharmaceuticals Inc. compared to the market average is the variable Other Net Income, increasing the Economic Capital Ratio by 99% points. The greatest weakness of KalVista Pharmaceuticals Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 138% points.

The company's Economic Capital Ratio, given in the ranking table, is -51%, being 303% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	88,696
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	7,720
Liabilities, Non-Current	1,057
Other Assets	1,790
Other Compr. Net Income	44
Other Expenses	-124
Other Liabilities	0
Other Net Income	11,293
Property and Equipment	2,043
Research and Development	40,194
Revenues	12,690
Selling, General and Administrative Expense	13,029

Output Variable	Value in 1000 USD
Assets	92,529
Liabilities	8,777
Expenses	53,099
Stockholders Equity	83,752
Net Income	-29,116
Comprehensive Net Income	-29,094
Economic Capital Ratio	-51%

